I give Tofacitinib a 75% chance to be endorsed by a solid plurality of the advisory panel (i.e. something better than a 7-5 or 8-7 vote in favor). Does anyone here agree/disagree?
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.